Biotech Values

[DewDiligence]

NICE requests more data on Roche’s Zelboraf before agreeing to reimburse at lower rate:

http://www.bloomberg.com/news/2012-08-09/roche-s-skin-cancer-treatment-delayed-by-u-k-drug-cost-a.html

NICE, which advises the state-run National Health Service on the treatments that represent value for money, refused to back Zelboraf for approval after the first consultation in June [#msg-76635851]. Roche offered to cut the price of the drug, which costs about 1,750 pounds ($2,734) a week in the U.K. The average duration of treatment is seven months, which would cost 52,500 pounds, NICE said. The amount of the offered discount is confidential, the authority said.